Immunovant, Inc. (IMVT) is a publicly traded company in the Healthcare — Biotechnology industry listed on NASDAQ. This overview shows the latest price, key valuation ratios, profitability metrics and financial-health indicators used by fundamental investors.
Immunovant, Inc. is a biopharmaceutical firm in the clinical development phase, dedicated to advancing novel monoclonal antibody therapies for the treatment of various autoimmune conditions. The company's primary focus is batoclimab, a pioneering, fully human monoclonal antibody. This antibody is engineered to specifically target and block the neonatal fragment crystallizable receptor (FcRn), a key mechanism in certain autoimmune diseases.
Is Immunovant, Inc. stock overvalued or undervalued in 2026?
As of November 2, 2026, Immunovant, Inc. (IMVT) trades at $28.41 with no positive earnings over the last twelve months, according to Kaplio. No valuation verdict: it has no earnings to calculate a P/E from.
Kaplio overview: Immunovant, Inc.
Market cap $6B · 52 weeks $22 – $45 (37 % below the high) · P/E no earnings · Dividend none · Next earnings November 9, 2026 · expected EPS -$0.74 · Closing price, Nov 2 · accounts published Aug 6.
- Valuation: P/E — (no earnings).
- Balance sheet: Safe zone (solid).
- Earnings: 3 of 8 (disappointing).
What would it be worth at its usual multiples?
No valuation verdict: it has no earnings to calculate a P/E from.
What matters in biotech: 2 of 4 pass
- R&D / Market cap 0.0 %, fails.
- Market cap / Cash 5.7×, fails.
- Cash Runway 27 months, passes.
- Total Debt 0.0×, passes.
- Annual cash burn $2.23, info.
Against its peers (reference peers) — Immunovant, Inc.: P/E —; EV/EBITDA —; ROIC -75.9 %; $5.9B. TG Therapeutics, Inc. (P/E 21.9×; EV/EBITDA 70.4×; ROIC 9.9 %; $9.2B), Ligand Pharmaceuticals Incorporated (P/E 137×; EV/EBITDA 93.2×; ROIC 2.3 %; $6.1B), PTC Therapeutics, Inc. (P/E —; EV/EBITDA 29.9×; ROIC 5.7 %; $5.1B).
Profitability
| Return on Equity | -69.59% |
| Return on Invested Capital | -75.90% |
| Return on Assets | -63.13% |
| Gross Margin | 97.10% |
| Operating Margin | -7,877.46% |
| Net Margin | -7,585.86% |
Financial Health
| Debt / Equity | 0.00 |
| Current Ratio | 7.27 |
| Piotroski F-Score | 1 |
| Altman Z-Score | 22.57 |
Price Performance
| 1 month | -15.50% |
| 3 months | -27.67% |
| Year-to-date | +11.76% |
| 1 year | +19.47% |
| 3 years | -16.42% |
| 5 years | +225.80% |
Related companies: TGTX · VRTX · 0QZU.L · REGN · MRNA · 0R2M.L · ARGX · 0QNO.L
Explore sector: Healthcare · Biotechnology
More sections of IMVT: Financials · Valuation · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Weekly Radar: the S&P 500 through the Buffett and Lynch methods · Companies that pass the Buffett method · Companies that pass the Lynch method · Stocks that pass Graham's defensive investor test today · Investment Academy — learn to analyze stocks